Trial reportThe journals of gerontology. Series A, Biological sciences and medical sciences2019
The Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine on the Physical Functioning and Quality of Life of Older Adults: An Open-Label, Phase III Trial.
Trial report in The journals of gerontology. Series A, Biological sciences and medical sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02979639 (Study to Evaluate the Impact of Reactogenicity on Quality of Life), which is not on this map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GSK Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age
Who cites it
22 citing papers in PubMed, 33 citations in OpenAlex.
- Safety of Simultaneous vs Sequential mRNA COVID-19 and Inactivated Influenza Vaccines: A Randomized Clinical Trial.JAMA network open · 2024Trial
- Safety of Simultaneous Vaccination With Adjuvanted Zoster Vaccine and Adjuvanted Influenza Vaccine: A Randomized Clinical Trial.JAMA network open · 2024Trial
- Impact of Reactogenicity After Two Doses of Recombinant Zoster Vaccine Upon Physical Functioning and Quality of Life: An Open Phase III Trial in Older Adults.The journals of gerontology. Series A, Biological sciences and medical sciences · 2021Trial
- Evaluation of two frailty indices, with practical application in a vaccine clinical trial.Human vaccines & immunotherapeutics · 2019Trial
- Herpes Zoster in Aging Patients: Risk Factors and Prevention Strategies.International journal of general medicine · 2026Review
- Public Health Impact and Cost-Effectiveness of Adjuvanted RSVPreF3 Vaccination among Adults in the USA Aged 50-59 Years at Increased Risk of Severe RSV Disease.Infectious diseases and therapy · 2025Article
- Impact of Inactivated Influenza Vaccination on Health-Related Quality of Life Among Japanese Healthcare Workers.Immunity, inflammation and disease · 2025Article
- First case of lupus induced by the Shingrix vaccine: a case report and literature review.Clinical rheumatology · 2025Review
- Cost-effectiveness of the adjuvanted RSVPreF3 vaccine among adults aged ≥60 years in the United States.Human vaccines & immunotherapeutics · 2024Article
- Article
- Preclinical immunogenicity of an adenovirus-vectored vaccine for herpes zoster.Human vaccines & immunotherapeutics · 2023Article
- Recombinant zoster vaccine in immunocompetent and immunocompromised adults: A review of clinical studies.Human vaccines & immunotherapeutics · 2023Review
- Pre-Clinical Development of an Adenovirus Vector Based RSV and Shingles Vaccine Candidate.Vaccines · 2023Article
- Comparative Cost-Effectiveness Analysis of Respiratory Syncytial Virus Vaccines for Older Adults in Hong Kong.Vaccines · 2023Article
- Patient-reported outcomes in vaccines research: relevance for decision-making.Human vaccines & immunotherapeutics · 2022Review
- Headache After Vaccination: An Update on Recent Clinical Trials and Real-World Reporting.Current pain and headache reports · 2022Review
- Associations between vaccination and quality of life among Taiwan general population: A comparison between COVID-19 vaccines and flu vaccines.Human vaccines & immunotherapeutics · 2022Article
- Early examination of real-world uptake and second-dose completion of recombinant zoster vaccine in the United States from October 2017 to September 2019.Human vaccines & immunotherapeutics · 2021Article
- Considering Frailty in SARS-CoV-2 Vaccine Development: How Geriatricians Can Assist.Clinical interventions in aging · 2021Review
- Safety and reactogenicity of the adjuvanted recombinant zoster vaccine: experience from clinical trials and post-marketing surveillance.Therapeutic advances in vaccines and immunotherapy · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 8 institutions in 2 countries.
Funding
Abstract
backgroundHerpes zoster and its related complications are associated with significant medical burden, which negatively affects quality of life and daily functioning of the patients. The recently licensed recombinant zoster vaccine (RZV) offers high efficacy but is associated with local and systemic reactions. This study assessed the impact of RZV on the quality of life and daily functioning of participants and implications for caregivers.
methodsFour hundred and one adults aged 50 years or older received single RZV doses at 0 and 2 months in this open-label, single-arm, multicenter study (NCT02979639). Change in mean SF-36 Physical Functioning score following first-dose administration, quality of life, reactogenicity, safety, productivity loss, and health care resource utilization was assessed. The current analysis was performed post-vaccine dose-1; safety follow-up will continue until 1 year post-dose-2.
resultsThe most common solicited local symptoms were injection-site pain (77.5%), redness (23.0%), and swelling (13.3%); the most frequent solicited systemic reactions were fatigue (33.5%), headache (28.3%), and myalgia (26.8%). Grade 3 reactogenicity occurred in 9.5% of participants and was associated with a transient clinically important decrease in SF-36 Physical Functioning score (affecting activities such as walking, carrying groceries, climbing stairs) on Days 1 and 2 post-first vaccination. No clinically meaningful reductions in mean SF-36 Physical Functioning scale scores from pre- to post-RZV dose-1 were observed (mean +1.9 points, primary end point), and no overall quality-adjusted-life-year loss was recorded post-dose-1. Five participants reported lost workdays; caregiver workload was not increased.
conclusionsOverall, the physical functioning and quality of life of older adults were not affected by a first RZV dose. The observed reactogenicity was consistent with previous studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.